Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOD1 | P00441 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 16/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3845720 | 0.92 | NR1H2 (0.33) | ESR1STSRORCNR1H2NR1H3 | |
| SCHEMBL3851828 | 0.89 | CA2 (0.40) | SOD1CA2ESR1CA1STS | |
| SCHEMBL5149829 | 0.87 | CA2 (0.41) | SOD1CA2ESR1CA1STS | |
| SCHEMBL3845724 | 0.87 | CA2 (0.41) | SOD1CA2ESR1CA1STS | |
| SCHEMBL2214509 | 0.87 | CA2 (0.41) | SOD1CA2ESR1CA1STS | |
| SCHEMBL5172821 | 0.87 | CA2 (0.41) | SOD1CA2ESR1CA1STS | |
| SCHEMBL3845551 | 0.87 | CA2 (0.30) | CA2 | |
| SCHEMBL3846671 | 0.86 | CA2 (0.30) | CA2 | |
| SCHEMBL2213456 | 0.84 | CA2 (0.35) | SOD1CA2ESR1CA1STS | |
| SCHEMBL4589116 | 0.82 | MAPK1 (0.41) | SOD1ESR1STSNR3C1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2039702-A2 | Prodrugs erbeta-selective substances, method for their production and pharmaceutical compounds containing these compositions | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-25 | — | — | EP | claimed |
| EP-1957515-A2 | PRODRUG ERbeta-SELECTIVE SUBSTANCES, METHODS FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-08-20 | — | — | EP | claimed |
| WO-2007062877-A2 | PRODRUG ERβ-SELECTIVE SUBSTANCES, METHODS FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-06-07 | — | — | WO | claimed |
| US-20070123500-A1 | Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-31 | — | — | US | claimed |
| EP-2039702-A2 | Prodrugs erbeta-selective substances, method for their production and pharmaceutical compounds containing these compositions | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-25 | — | — | EP | disclosed |
| EP-1957515-A2 | PRODRUG ERbeta-SELECTIVE SUBSTANCES, METHODS FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007062877-A2 | PRODRUG ERβ-SELECTIVE SUBSTANCES, METHODS FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123500-A1 | Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds | CYP19A1, ESR2, HSD17B11 | SOD1 2674/4885CA2 326/4885ESR1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.